Symbols / SABS $3.76 -7.74%
SABS Chart
About
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 178.76M |
| Enterprise Value | 116.73M | Income | 4.26M | Sales | — |
| Book/sh | 3.18 | Cash/sh | 1.90 | Dividend Yield | — |
| Payout | 0.00% | Employees | 86 | IPO | — |
| P/E | — | Forward P/E | -11.38 | PEG | — |
| P/S | — | P/B | 1.18 | P/C | — |
| EV/EBITDA | -2.54 | EV/Sales | — | Quick Ratio | 9.13 |
| Current Ratio | 9.46 | Debt/Eq | 3.93 | LT Debt/Eq | — |
| EPS (ttm) | -1.56 | EPS next Y | -0.33 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-09 17:00 | ROA | -28.20% |
| ROE | 14.96% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 47.61M |
| Shs Float | 22.46M | Short Float | 3.53% | Short Ratio | 4.77 |
| Short Interest | — | 52W High | 6.60 | 52W Low | 1.00 |
| Beta | 0.61 | Avg Volume | 452.78K | Volume | 1.75M |
| Target Price | $9.50 | Recom | Strong_buy | Prev Close | $4.07 |
| Price | $3.75 | Change | -7.74% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.50
Mean price target
2. Current target
$3.80
Latest analyst target
3. DCF / Fair value
$-8.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.80
Low
$6.00
High
$15.00
Mean
$9.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | main | Chardan Capital | Buy → Buy | $14 |
| 2026-03-10 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2026-01-07 | init | UBS | — → Buy | $7 |
| 2025-12-19 | init | Guggenheim | — → Buy | $15 |
| 2025-12-18 | main | Chardan Capital | Buy → Buy | $12 |
| 2025-11-17 | main | Chardan Capital | Buy → Buy | $12 |
| 2025-09-19 | main | Chardan Capital | Buy → Buy | $12 |
| 2025-09-17 | init | Leerink Partners | — → Outperform | $7 |
| 2025-08-08 | main | Chardan Capital | Buy → Buy | $12 |
| 2025-07-22 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2025-05-15 | main | Chardan Capital | Buy → Buy | $20 |
| 2025-04-01 | main | Chardan Capital | Buy → Buy | $20 |
| 2025-04-01 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2025-01-29 | main | Chardan Capital | Buy → Buy | $25 |
| 2025-01-29 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-11-07 | main | Chardan Capital | Buy → Buy | $25 |
| 2024-10-09 | init | Craig-Hallum | — → Buy | $11 |
| 2024-09-12 | reit | Oppenheimer | Outperform → Outperform | $12 |
| 2024-09-09 | main | Chardan Capital | Buy → Buy | $25 |
| 2024-08-28 | init | Oppenheimer | — → Outperform | $12 |
- SAB BIO plans $85M funding push for experimental type 1 diabetes treatment - Stock Titan Wed, 18 Mar 2026 02
- SAB Biotherapeutics, Inc. Prices Public Offering of Common Stock and Pre-Funded Warrants to Raise Approximately $85 Million - Quiver Quantitative Wed, 18 Mar 2026 02
- Sab Bio Announces Pricing Of $85 Million Public Offering Of Common Stock At $3.85 Per Share - TradingView Wed, 18 Mar 2026 02
- SAB Biotherapeutics slips 5%, prices $85M stock offering - MSN Wed, 18 Mar 2026 12
- Sab Bio announces pricing of $85 million public offering of common stock at $3.85 per share - marketscreener.com Wed, 18 Mar 2026 03
- SAB Biotherapeutics announces common stock offering, no amount given - TipRanks Wed, 18 Mar 2026 05
- Biotech SAB BIO plans stock sale to fund Type 1 diabetes trials - Stock Titan ue, 17 Mar 2026 20
- SAB Biotherapeutics announces public stock offering; shares down - MSN ue, 17 Mar 2026 21
- SAB Biotherapeutics, Inc.'s (NASDAQ:SABS) biggest owners are individual investors who got richer after stock soared 22% last week - Yahoo Finance Sat, 22 Nov 2025 08
- SAB Biotherapeutics (SABS) to offer common stock and pre-funded warrants - Stock Titan ue, 17 Mar 2026 20
- SAB Biotherapeutics 19.325M share Spot Secondary priced at $3.85 - TipRanks Wed, 18 Mar 2026 12
- Diabetes drug developer SAB Biotherapeutics at two Miami investor events - Stock Titan Mon, 02 Mar 2026 08
- SAB BIO backs diabetes therapy with $175M and 2027 trial goal - Stock Titan Mon, 09 Mar 2026 07
- Analysts Offer Insights on Healthcare Companies: Rapport Therapeutics, Inc. (RAPP), SAB Biotherapeutics (SABS) and Encompass Health (EHC) - The Globe and Mail Fri, 13 Mar 2026 08
- Two veteran drug leaders join the board behind a new Type 1 diabetes therapy - Stock Titan Wed, 07 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1740000 | 3045000 | — | Conversion of Exercise of derivative security at price 1.75 per share. | SESSA CAPITAL MASTER, L.P. | Beneficial Owner of more than 10% of a Class of Security | — | 2025-09-29 00:00:00 | I |
| 1 | 1740000 | 3045000 | — | Conversion of Exercise of derivative security at price 1.75 per share. | MOIN ANDREW D. | Director | — | 2025-09-29 00:00:00 | I |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 2.18M | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.21 | 0.00 |
| NormalizedEBITDA | -34.38M | -33.31M | -25.52M | -11.71M |
| TotalUnusualItems | 5.39M | -4.82M | 10.40M | -3.49M |
| TotalUnusualItemsExcludingGoodwill | 5.39M | -4.82M | 10.40M | -3.49M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -34.11M | -42.19M | -18.74M | -17.14M |
| ReconciledDepreciation | 4.79M | 3.75M | 3.29M | 1.65M |
| EBITDA | -28.99M | -38.13M | -15.12M | -15.20M |
| EBIT | -33.79M | -41.88M | -18.41M | -16.85M |
| NetInterestIncome | 967.60K | 269.68K | -230.51K | -271.34K |
| InterestExpense | 318.40K | 315.28K | 301.58K | 294.46K |
| InterestIncome | 1.29M | 584.97K | 71.07K | 23.11K |
| NormalizedIncome | -39.49M | -37.37M | -26.96M | -13.66M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -34.11M | -42.19M | -18.74M | -17.14M |
| TotalExpenses | 42.91M | 38.08M | 28.92M | 13.39M |
| TotalOperatingIncomeAsReported | -42.91M | -38.08M | -28.92M | -13.39M |
| DilutedAverageShares | 9.26M | 5.52M | 4.35M | 2.73M |
| BasicAverageShares | 9.26M | 5.52M | 4.35M | 2.73M |
| DilutedEPS | -3.68 | -7.64 | -4.31 | -6.30 |
| BasicEPS | -3.68 | -7.64 | -4.31 | -6.30 |
| DilutedNIAvailtoComStockholders | -34.11M | -42.19M | -18.74M | -17.14M |
| NetIncomeCommonStockholders | -34.11M | -42.19M | -18.74M | -17.14M |
| NetIncome | -34.11M | -42.19M | -18.74M | -17.14M |
| NetIncomeIncludingNoncontrollingInterests | -34.11M | -42.19M | -18.74M | -17.14M |
| NetIncomeContinuousOperations | -34.11M | -42.19M | -18.74M | -17.14M |
| TaxProvision | 0.00 | 25.63K | 0.00 | |
| PretaxIncome | -34.11M | -42.19M | -18.72M | -17.14M |
| OtherIncomeExpense | 7.84M | -4.39M | 10.43M | -3.48M |
| OtherNonOperatingIncomeExpenses | 2.45M | 435.09K | 33.75K | 5.49K |
| SpecialIncomeCharges | 0.00 | 665.60K | ||
| OtherSpecialCharges | -665.60K | |||
| GainOnSaleOfSecurity | 5.39M | -4.82M | 10.40M | -4.15M |
| NetNonOperatingInterestIncomeExpense | 967.60K | 269.68K | -230.51K | -271.34K |
| InterestExpenseNonOperating | 318.40K | 315.28K | 301.58K | 294.46K |
| InterestIncomeNonOperating | 1.29M | 584.97K | 71.07K | 23.11K |
| OperatingIncome | -42.91M | -38.08M | -28.92M | -13.39M |
| OperatingExpense | 42.91M | 38.08M | 28.92M | 13.39M |
| OtherOperatingExpenses | -1.32M | -2.24M | -23.90M | -60.88M |
| ResearchAndDevelopment | 30.25M | 16.52M | 36.44M | 57.18M |
| SellingGeneralAndAdministration | 13.98M | 23.80M | 16.38M | 17.09M |
| GeneralAndAdministrativeExpense | 13.98M | 23.80M | 16.38M | 17.09M |
| OtherGandA | 13.98M | 23.80M | 16.38M | 17.09M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 54.66K | 54.66K | 54.66K | |
| OrdinarySharesNumber | 9.29M | 9.23M | 5.04M | 4.35M |
| ShareIssued | 9.34M | 9.28M | 5.09M | 4.35M |
| TotalDebt | 4.67M | 5.91M | 5.93M | 8.52M |
| TangibleBookValue | 25.97M | 57.30M | 31.06M | 38.55M |
| InvestedCapital | 26.25M | 58.35M | 32.37M | 40.35M |
| WorkingCapital | 15.81M | 48.09M | 7.10M | 23.74M |
| NetTangibleAssets | 25.97M | 57.30M | 31.06M | 38.55M |
| CapitalLeaseObligations | 4.39M | 4.86M | 4.61M | 6.72M |
| CommonStockEquity | 25.97M | 57.30M | 31.06M | 38.55M |
| PreferredStockEquity | 5.00 | 5.00 | ||
| TotalCapitalization | 25.97M | 57.30M | 31.60M | 38.55M |
| TotalEquityGrossMinorityInterest | 25.97M | 57.30M | 31.06M | 38.55M |
| StockholdersEquity | 25.97M | 57.30M | 31.06M | 38.55M |
| GainsLossesNotAffectingRetainedEarnings | -135.41K | 26.42K | 0.00 | |
| OtherEquityAdjustments | -135.41K | 26.42K | ||
| TreasuryStock | 5.52M | 5.52M | 5.52M | 0.00 |
| RetainedEarnings | -124.17M | -90.06M | -47.87M | -29.13M |
| AdditionalPaidInCapital | 155.79M | 152.86M | 84.45M | 67.67M |
| CapitalStock | 940.00 | 934.00 | 510.00 | 4.35K |
| CommonStock | 935.00 | 929.00 | 510.00 | 4.35K |
| PreferredStock | 5.00 | 5.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 18.23M | 26.64M | 19.85M | 42.59M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 10.25M | 15.83M | 4.85M | 16.14M |
| DerivativeProductLiabilities | 6.39M | 11.77M | 320.93K | 10.72M |
| LongTermDebtAndCapitalLeaseObligation | 3.86M | 4.05M | 4.53M | 5.42M |
| LongTermCapitalLeaseObligation | 3.86M | 4.05M | 3.99M | 5.42M |
| LongTermDebt | 541.64K | |||
| CurrentLiabilities | 7.98M | 10.81M | 14.99M | 26.46M |
| OtherCurrentLiabilities | 6.34M | |||
| CurrentDeferredLiabilities | 0.00 | 1.32M | 0.00 | 100.00K |
| CurrentDeferredRevenue | 0.00 | 1.32M | 0.00 | 100.00K |
| CurrentDebtAndCapitalLeaseObligation | 811.84K | 1.85M | 1.40M | 3.10M |
| CurrentCapitalLeaseObligation | 535.99K | 801.95K | 623.58K | 1.30M |
| CurrentDebt | 275.85K | 1.05M | 772.66K | 1.80M |
| OtherCurrentBorrowings | 1.80M | |||
| CurrentNotesPayable | 275.85K | 1.05M | 772.66K | 1.80M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.99M | 1.46M | 2.36M | |
| PayablesAndAccruedExpenses | 7.17M | 7.64M | 12.13M | 14.56M |
| CurrentAccruedExpenses | 4.99M | 5.23M | 3.50M | 4.78M |
| InterestPayable | 22.44K | 78.00K | 8.19K | 0.00 |
| Payables | 2.17M | 2.41M | 8.64M | 9.78M |
| OtherPayable | 479.25K | 1.46M | 4.91M | 5.10M |
| DuetoRelatedPartiesCurrent | 0.00 | 2.37K | ||
| TotalTaxPayable | 40.00K | 50.00K | 216.25K | |
| AccountsPayable | 1.69M | 945.93K | 3.68M | 4.46M |
| TotalAssets | 44.20M | 83.94M | 50.90M | 81.14M |
| TotalNonCurrentAssets | 20.40M | 25.03M | 28.81M | 30.95M |
| NonCurrentPrepaidAssets | 221.00K | 350.23K | 467.69K | 0.00 |
| NonCurrentDeferredAssets | 261.11K | 0.00 | ||
| NetPPE | 19.92M | 24.68M | 28.34M | 30.95M |
| AccumulatedDepreciation | -14.57M | -9.91M | -6.28M | -3.22M |
| GrossPPE | 34.50M | 34.60M | 34.62M | 34.17M |
| Leases | 7.06M | 9.30M | 9.30M | 5.70M |
| ConstructionInProgress | 0.00 | 308.32K | 4.61M | |
| OtherProperties | 15.90M | 14.36M | 14.09M | 14.07M |
| MachineryFurnitureEquipment | 11.53M | 10.94M | 10.92M | 9.79M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 23.79M | 58.91M | 22.10M | 50.19M |
| OtherCurrentAssets | 2.98M | 2.34M | 1.49M | |
| RestrictedCash | 0.00 | 6.34M | ||
| PrepaidAssets | 1.49M | 2.64M | ||
| Receivables | 54.95K | 0.00 | 5.56M | 8.01M |
| AccruedInterestReceivable | 54.95K | 0.00 | ||
| AccountsReceivable | 0.00 | 5.56M | 8.01M | |
| CashCashEquivalentsAndShortTermInvestments | 20.76M | 56.57M | 15.05M | 33.21M |
| OtherShortTermInvestments | 11.86M | 0.00 | ||
| CashAndCashEquivalents | 8.90M | 56.57M | 15.05M | 33.21M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -34.63M | -25.32M | -25.63M | -8.96M |
| RepurchaseOfCapitalStock | 0.00 | -5.52M | 0.00 | |
| RepaymentOfDebt | -1.42M | -1.16M | -2.42M | -1.30M |
| IssuanceOfDebt | 515.99K | 765.19K | 1.24M | 2.84M |
| IssuanceOfCapitalStock | 0.00 | 7.50M | 7.68M | 0.00 |
| CapitalExpenditure | -337.26K | -197.15K | -2.17M | -10.94M |
| InterestPaidSupplementalData | 373.95K | 245.48K | 293.39K | 294.46K |
| EndCashPosition | 8.90M | 56.57M | 15.05M | 39.55M |
| BeginningCashPosition | 56.57M | 15.05M | 39.55M | 12.61M |
| EffectOfExchangeRateChanges | -241.20K | 18.14K | 0.00 | |
| ChangesInCash | -47.43M | 41.50M | -24.50M | 26.93M |
| FinancingCashFlow | -1.17M | 66.77M | 1.05M | 35.89M |
| CashFlowFromContinuingFinancingActivities | -1.17M | 66.77M | 1.05M | 35.89M |
| NetOtherFinancingCharges | -286.04K | 34.34M | 34.34M | |
| ProceedsFromStockOptionExercised | 20.41K | 59.66M | 76.97K | 6.75K |
| NetPreferredStockIssuance | 0.00 | 7.50M | 0.00 | |
| PreferredStockIssuance | 0.00 | 7.50M | 0.00 | |
| NetCommonStockIssuance | 0.00 | 2.16M | 0.00 | |
| CommonStockPayments | 0.00 | -5.52M | 0.00 | |
| CommonStockIssuance | 0.00 | 7.68M | 0.00 | |
| NetIssuancePaymentsOfDebt | -907.00K | -390.44K | -1.19M | 1.54M |
| NetLongTermDebtIssuance | -907.00K | -390.44K | -1.19M | 1.54M |
| LongTermDebtPayments | -1.42M | -1.16M | -2.42M | -1.30M |
| LongTermDebtIssuance | 515.99K | 765.19K | 1.24M | 2.84M |
| InvestingCashFlow | -11.96M | -152.70K | -2.09M | -10.94M |
| CashFlowFromContinuingInvestingActivities | -11.96M | -152.70K | -2.09M | -10.94M |
| NetInvestmentPurchaseAndSale | -11.63M | 0.00 | ||
| SaleOfInvestment | 25.82M | 0.00 | ||
| PurchaseOfInvestment | -37.45M | 0.00 | ||
| NetPPEPurchaseAndSale | -337.26K | -152.70K | -2.09M | -10.94M |
| SaleOfPPE | 0.00 | 44.45K | 76.39K | 0.00 |
| PurchaseOfPPE | -337.26K | -197.15K | -2.17M | -10.94M |
| OperatingCashFlow | -34.29M | -25.12M | -23.46M | 1.99M |
| CashFlowFromContinuingOperatingActivities | -34.29M | -25.12M | -23.46M | 1.99M |
| ChangeInWorkingCapital | -2.30M | 2.33M | -237.57K | 11.68M |
| ChangeInOtherWorkingCapital | -1.35M | 1.71M | -100.00K | |
| ChangeInOtherCurrentAssets | 387.30K | 53.44K | -63.63K | |
| ChangeInPayablesAndAccruedExpense | -307.70K | -4.42M | -3.32M | 446.32K |
| ChangeInAccruedExpense | -1.23M | -1.71M | -2.54M | 3.38M |
| ChangeInPayable | 923.32K | -2.70M | -781.79K | -2.94M |
| ChangeInAccountPayable | 923.32K | -2.70M | -779.42K | -2.94M |
| ChangeInPrepaidAssets | -590.46K | -523.61K | 674.55K | -1.26M |
| ChangeInReceivables | -54.95K | 5.56M | 2.45M | 12.56M |
| ChangesInAccountReceivables | 0.00 | 5.56M | 2.45M | 12.56M |
| OtherNonCashItems | -237.09K | 3.71M | -32.21K | |
| StockBasedCompensation | 2.94M | 2.42M | 2.67M | 2.31M |
| DepreciationAmortizationDepletion | 4.79M | 3.75M | 3.29M | 1.65M |
| DepreciationAndAmortization | 4.79M | 3.75M | 3.29M | 1.65M |
| Depreciation | 4.79M | 3.75M | 3.29M | 1.65M |
| OperatingGainsLosses | -5.39M | 4.87M | -10.42M | 3.48M |
| GainLossOnInvestmentSecurities | -5.39M | 4.82M | -10.40M | 4.15M |
| GainLossOnSaleOfPPE | 0.00 | 44.49K | -15.80K | -5.49K |
| NetIncomeFromContinuingOperations | -34.11M | -42.19M | -18.74M | -17.14M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for SABS
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|